HRP20140845T1 - Soli rasagilina i farmaceutski pripravci od njih - Google Patents
Soli rasagilina i farmaceutski pripravci od njih Download PDFInfo
- Publication number
- HRP20140845T1 HRP20140845T1 HRP20140845AT HRP20140845T HRP20140845T1 HR P20140845 T1 HRP20140845 T1 HR P20140845T1 HR P20140845A T HRP20140845A T HR P20140845AT HR P20140845 T HRP20140845 T HR P20140845T HR P20140845 T1 HRP20140845 T1 HR P20140845T1
- Authority
- HR
- Croatia
- Prior art keywords
- acid
- rasagiline
- salt
- salt according
- injuries
- Prior art date
Links
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical class C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title claims 12
- 229960000245 rasagiline Drugs 0.000 title claims 10
- 150000003839 salts Chemical class 0.000 title claims 8
- 239000000825 pharmaceutical preparation Chemical class 0.000 title claims 2
- 239000002253 acid Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
- ISYWECDDZWTKFF-UHFFFAOYSA-N nonadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)=O ISYWECDDZWTKFF-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 230000000472 traumatic effect Effects 0.000 claims 2
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 claims 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 239000005639 Lauric acid Substances 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 235000021319 Palmitoleic acid Nutrition 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000020339 Spinal injury Diseases 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 1
- 229940114079 arachidonic acid Drugs 0.000 claims 1
- 235000021342 arachidonic acid Nutrition 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 229960004488 linolenic acid Drugs 0.000 claims 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 231100000189 neurotoxic Toxicity 0.000 claims 1
- 230000002887 neurotoxic effect Effects 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- 229960002969 oleic acid Drugs 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/122—Propionic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/126—Acids containing more than four carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C07C57/12—Straight chain carboxylic acids containing eighteen carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (10)
1. Sol rasagilina s kiselinom, naznačena time, da je sol pri 23°C tekuća, gdje kiselina ima opću formulu R-COOH, a R je zasićeni ili nezasićeni, razgranani ili nerazgranani C2-C23 alkil.
2. Sol prema patentnom zahtjevu 1, naznačena time, da R jest zasićeni ili nezasićeni, nerazgranani C2-C19 alkil.
3. Sol prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da se kiselina odabire iz skupine koja obuhvaća propionsku kiselinu, maslačnu kiselinu, pentan kiselinu, heksan kiselinu, heptan kiselinu, oktan kiselinu, nonan kiselinu, dekan kiselinu, undekan kiselinu, laurinsku kiselinu, tridekan kiselinu, miristinsku kiselinu, pentadekan kiselinu, palmitinsku kiselinu, heptadekan kiselinu, stearinsku kiselinu, nonadekan kiselinu, arahidinsku kiselinu, palmitoleinsku kiselinu, oleinsku kiselinu, sorbinsku kiselinu, linolnu kiselinu, linolensku kiselinu i arahidonsku kiselinu.
4. Sol prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da se odabire iz skupine koja obuhvaća rasagilin heksanoat, rasagilin oktanoat, rasagilin dekanoat i rasagilin oleat.
5. Farmaceutski pripravak, naznačen time, da sadrži sol rasagilina prema bilo kojem od patentnih zahtjeva 1-4.
6. Uporaba soli rasagilina prema bilo kojem od patentnih zahtjeva 1-4, naznačena time, da jest za proizvodnju lijeka za liječenje Parkinsonove bolesti, poremećaja pamćenja, demencije, depresije, sindroma hiperaktivnosti, afektivne bolesti, neurodegenerativne bolesti, neurotoksične povrede, ishemije mozga, traumatske ozljede glave, traumatske ozljede kralješnice, shizofrenije, poremećaja deficita pažnje, multiple skleroze ili apstinencijskih simptoma.
7. Postupak za pripremu soli rasagilina prema bilo kojem od patentnih zahtjeva 1-4, naznačen time, da obuhvaća stupnjeve miješanja rasagilina i kiseline, te dobivanje soli.
8. Postupak prema patentnom zahtjevu 7, naznačen time, da se rasagilin i kiselina miješanju uz primjenu miješalice.
9. Postupak prema patentnom zahtjevu 7, naznačen time, da se rasagilin i kiselina miješaju u prisutnosti otapala.
10. Postupak prema patentnom zahtjevu 9, naznačen time, da otapalo jest diizopropileter ili aceton.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1632CH2009 | 2009-07-09 | ||
| PCT/EP2010/059723 WO2011003938A1 (en) | 2009-07-09 | 2010-07-07 | Salts of rasagiline and pharmaceutical preparations thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140845T1 true HRP20140845T1 (hr) | 2014-11-07 |
Family
ID=42634609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140845AT HRP20140845T1 (hr) | 2009-07-09 | 2014-09-08 | Soli rasagilina i farmaceutski pripravci od njih |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8946482B2 (hr) |
| EP (1) | EP2451771B1 (hr) |
| JP (1) | JP2012532843A (hr) |
| AU (1) | AU2010270254A1 (hr) |
| CA (1) | CA2767592A1 (hr) |
| CY (1) | CY1115595T1 (hr) |
| DK (1) | DK2451771T3 (hr) |
| ES (1) | ES2503015T3 (hr) |
| HR (1) | HRP20140845T1 (hr) |
| IL (1) | IL217239A0 (hr) |
| PL (1) | PL2451771T3 (hr) |
| PT (1) | PT2451771E (hr) |
| RS (1) | RS53504B1 (hr) |
| SI (1) | SI2451771T1 (hr) |
| WO (1) | WO2011003938A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007217349B9 (en) | 2006-02-21 | 2013-06-27 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Multiple System Atrophy |
| WO2007117431A2 (en) | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| ZA200903903B (en) | 2006-12-14 | 2010-08-25 | Teva Pharma | Crystalline solid rasagiline base |
| US8188149B2 (en) | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| EP2299993A4 (en) | 2008-06-19 | 2014-08-20 | Teva Pharma | PROCESS FOR PURIFYING THE BASE OF RASAGILINE |
| NZ589547A (en) | 2008-06-19 | 2013-03-28 | Teva Pharma | Dried rasagiline base having a water content less than 0.5 % by weight |
| US20100189788A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline base formulation |
| WO2011121607A2 (en) | 2010-03-29 | 2011-10-06 | Cadila Healthcare Limited | Rasagiline and its pharmaceutically acceptable salts |
| AU2011282720B2 (en) | 2010-07-27 | 2016-12-22 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| EP2598136A4 (en) | 2010-07-27 | 2015-03-25 | Teva Pharma | DISPERSIONS OF RASAGILINE CITRATE |
| HU231054B1 (hu) * | 2010-11-18 | 2020-04-28 | Egis Gyógyszergyár Nyrt. | Gyógyászati készítmény előállítására alkalmazható új sók |
| WO2012153349A2 (en) | 2011-05-04 | 2012-11-15 | Cadila Healthcare Limited | Rasagiline and its pharmaceutically acceptable salts |
| BR112014008555A2 (pt) | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-formil-propargil-aminoindano |
| WO2013055689A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | R(+)-n-methyl-propargyl-aminoindan |
| MX2015002062A (es) | 2012-08-17 | 2015-06-05 | Teva Pharma | Formulaciones parenterales de rasagilina. |
| WO2014192022A1 (en) * | 2013-05-20 | 2014-12-04 | Cadila Healthcare Limited | Pharmaceutical compositions of rasagiline |
| WO2015086768A1 (en) * | 2013-12-11 | 2015-06-18 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising a pharmaceutically acceptable salt of rasagiline |
| US20170197980A1 (en) * | 2014-06-25 | 2017-07-13 | Abbvie Inc. | N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate |
| CN111635305A (zh) * | 2020-07-01 | 2020-09-08 | 中山华明泰科技股份有限公司 | 一种复合异辛酸锌制备方法及应用 |
| CN116036055A (zh) * | 2023-03-16 | 2023-05-02 | 上海世领制药有限公司 | 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3253037A (en) * | 1962-06-19 | 1966-05-24 | Ciba Geigy Corp | N-2-alkynyl-amino-benzocylo-alkanes |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| IL115357A (en) | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| EP1535902B1 (en) | 1996-12-18 | 2007-11-07 | Teva Pharmaceutical Industries, Ltd. | Aminoindan derivatives |
| IL141690A (en) | 2001-02-27 | 2004-06-20 | Isp Finetech Ltd | Process for preparation of rasagiline and its salts |
| WO2004045515A2 (en) | 2002-11-15 | 2004-06-03 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
| AU2005269416B2 (en) | 2004-07-26 | 2011-07-28 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| CN101098685A (zh) | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
| BRPI0608209A2 (pt) | 2005-02-23 | 2010-11-09 | Teva Pharma | mistura de partìculas, composição sólida, método para tratamento de um paciente com mal de parkinson, processo para preparação de uma composição, e, composição farmacêutica sólida |
| WO2007061717A2 (en) | 2005-11-17 | 2007-05-31 | Teva Pharmaceutical Industries, Ltd. | Methods for isolating propargylated aminoindans |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| AU2007217349B9 (en) | 2006-02-21 | 2013-06-27 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Multiple System Atrophy |
| WO2007117431A2 (en) | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| EP2101570B1 (en) | 2006-12-14 | 2013-02-13 | Teva Pharmaceutical Industries, Ltd. | Tannate salt of rasagiline |
| ZA200903903B (en) | 2006-12-14 | 2010-08-25 | Teva Pharma | Crystalline solid rasagiline base |
| EP1987816A1 (de) | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| US20090062400A1 (en) | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| AU2009204454B2 (en) | 2008-01-11 | 2015-02-05 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations, their preparation and use |
| EP2285214B1 (en) | 2008-06-10 | 2012-05-16 | Teva Pharmaceutical Industries Ltd. | Rasagiline soft gelatin capsules |
| NZ589445A (en) | 2008-06-13 | 2013-06-28 | Teva Pharma | Rasagiline for parkinson's disease modification |
| EP2299993A4 (en) | 2008-06-19 | 2014-08-20 | Teva Pharma | PROCESS FOR PURIFYING THE BASE OF RASAGILINE |
| NZ589547A (en) | 2008-06-19 | 2013-03-28 | Teva Pharma | Dried rasagiline base having a water content less than 0.5 % by weight |
| DE102008064061A1 (de) | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US20100189788A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline base formulation |
| EP2485722A1 (en) | 2009-10-09 | 2012-08-15 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of progressive supranuclear palsy |
| EP2515891A4 (en) | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
| EP2598136A4 (en) | 2010-07-27 | 2015-03-25 | Teva Pharma | DISPERSIONS OF RASAGILINE CITRATE |
| AU2011282720B2 (en) | 2010-07-27 | 2016-12-22 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| SG10201508771TA (en) | 2010-10-26 | 2015-11-27 | Teva Pharma | Deuterium enriched rasagiline |
| CN103857389A (zh) | 2011-10-10 | 2014-06-11 | 泰华制药工业有限公司 | 雷沙吉兰柠檬酰胺 |
| BR112014008555A2 (pt) | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-formil-propargil-aminoindano |
| WO2013055689A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | R(+)-n-methyl-propargyl-aminoindan |
-
2010
- 2010-07-07 US US13/383,163 patent/US8946482B2/en not_active Expired - Fee Related
- 2010-07-07 EP EP10731734.9A patent/EP2451771B1/en active Active
- 2010-07-07 SI SI201030747T patent/SI2451771T1/sl unknown
- 2010-07-07 WO PCT/EP2010/059723 patent/WO2011003938A1/en active Application Filing
- 2010-07-07 RS RS20140389A patent/RS53504B1/en unknown
- 2010-07-07 AU AU2010270254A patent/AU2010270254A1/en not_active Abandoned
- 2010-07-07 ES ES10731734.9T patent/ES2503015T3/es active Active
- 2010-07-07 PT PT107317349T patent/PT2451771E/pt unknown
- 2010-07-07 PL PL10731734T patent/PL2451771T3/pl unknown
- 2010-07-07 JP JP2012518978A patent/JP2012532843A/ja not_active Withdrawn
- 2010-07-07 CA CA2767592A patent/CA2767592A1/en not_active Abandoned
- 2010-07-07 DK DK10731734.9T patent/DK2451771T3/da active
-
2011
- 2011-12-27 IL IL217239A patent/IL217239A0/en unknown
-
2014
- 2014-08-13 CY CY20141100647T patent/CY1115595T1/el unknown
- 2014-09-08 HR HRP20140845AT patent/HRP20140845T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012532843A (ja) | 2012-12-20 |
| EP2451771A1 (en) | 2012-05-16 |
| SI2451771T1 (sl) | 2014-10-30 |
| CY1115595T1 (el) | 2017-01-04 |
| US20120142966A1 (en) | 2012-06-07 |
| CA2767592A1 (en) | 2011-01-13 |
| ES2503015T3 (es) | 2014-10-06 |
| PT2451771E (pt) | 2014-09-19 |
| DK2451771T3 (da) | 2014-09-08 |
| IL217239A0 (en) | 2012-02-29 |
| AU2010270254A1 (en) | 2012-02-02 |
| WO2011003938A1 (en) | 2011-01-13 |
| US8946482B2 (en) | 2015-02-03 |
| PL2451771T3 (pl) | 2014-12-31 |
| EP2451771B1 (en) | 2014-06-18 |
| RS53504B1 (en) | 2015-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140845T1 (hr) | Soli rasagilina i farmaceutski pripravci od njih | |
| MA55632A (fr) | Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques | |
| SG10201903474PA (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| JP2018520205A5 (hr) | ||
| NZ628051A (en) | Process for preparing infant formula | |
| MY165048A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| FR3031462B1 (fr) | Procede et dispositif pour la fabrication par prelevement par aiguille creuse de composants et la distribution d'un produit cosmetique personnalise | |
| FR2949078B1 (fr) | Procede de preparation d'un catalyseur supporte ni/sn pour l'hydrogenation selective d'hydrocarbures polyinsatures | |
| EP2578691A4 (en) | PROCESS FOR PREPARING OIL OR FAT WITH A LIPASE-SUBSTANTIAL HIGH-UNSATURATED FATTY ACID | |
| FR2986704B1 (fr) | Procede de traitement cosmetique et composition comprenant un ester d'acide glyoxylique | |
| WO2010136000A3 (en) | Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them | |
| FR2978147B1 (fr) | Procede de synthese d'acides omega-fonctionnalises a partir d'acides ou esters gras hydroxyles | |
| BR112015014778A2 (pt) | preparação de aminas e diaminas a partir de um ácido carboxílico ou de um ácido dicarboxílico ou de um monoéster dos mesmos | |
| FR2969137B1 (fr) | Procede de preparation d'une composition de particules mixtes contenant des elements des colonnes 13 et 15 | |
| FR3002869B1 (fr) | Procede et installation de transformation d'un metal a l'etat liquide en un metal a l'etat solide | |
| IL246254B (en) | Compounds of omega-3 fatty acids for the treatment of diseases involving damage to the nervous system | |
| MX2015013511A (es) | Formulacion farmaceutica que comprende fosfatidilcolina para el tratamiento de colitis ulcerosa. | |
| FR2984869B1 (fr) | Procede de preparation d'un hydrogel comprenant des particules minerales silico-metalliques et hydrogel | |
| FR2994973B1 (fr) | Procede de production d'acide methacrylique | |
| FR2948659B1 (fr) | Procede de preparation des esters de l'acide difluoroacetique | |
| GB2528618B (en) | Chromatographic process for the production of highly purified polyunsaturated fatty acids | |
| GEP20186881B (en) | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| FR2991137B1 (fr) | Procede de preparation d’un melange comprenant des grains d’une plante du genre theobroma | |
| FR2955859B1 (fr) | Procede de preparation d'un ester d'acide carboxylique | |
| FR2997869B1 (fr) | Procede et installation pour la production de particules a partir d'un liquide d'interet |